REGENXBIO Inc. (RGNX) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, REGENXBIO Inc.'s filing signal turned negative.

REGENXBIO Inc. is a clinical-stage biotechnology company focused on developing gene therapies using its proprietary NAV(R) Technology Platform, which utilizes adeno-associated virus (AAV) vectors. The company aims to deliver functional genes to address genetic defects, potentially offering one-time treatments with long-lasting effects for various diseases. REGENXBIO's internal development pipeline targets retinal, neuromuscular, and neurodegenerative diseases, with key product candidates including surabgene lomparvovec (ABBV-RGX-314) for eye conditions, RGX-202 for Duchenne muscular dystrophy, and RGX-121 and RGX-111 for lysosomal storage disorders. The company has built integrated, end-to-end capabilities in research, development, manufacturing, and commercialization, leveraging its platform through internal programs and strategic partnerships with companies like AbbVie and Nippon Shinyaku.

REGENXBIO's revenues are primarily derived from license, royalty, and service revenues earned under its license and collaboration agreements. Key revenue streams include royalties from Novartis's Zolgensma and Itvisma, upfront and milestone payments from collaborations with AbbVie and Nippon Shinyaku, and fees for development and manufacturing services.